Pfizer Corporation

Pfizer Products Inc.

Karen Jean Coffman

Michael Aaron Brodney

Patrick Robert Verhoest

Matthew Richard Reese

Travis T Wager

Jaclyn Louise Henderson

Bethany Lyn Kormos

Martin Youngjin Pettersson

Antonia Friederike Stepan

Paul Galatsis

Michelle Renee Garnsey

Ravi G Kurumbail

Brian Thomas O'Neill

Yuhpyng Liang Chen

Jotham Wadsworth Coe

Christopher John Helal

Neelu Kaila

Thomas Allen Chappie

Tarek A Samad

Edward F Kleinman

Yuan Zhang

Jamison Bryce Tuttle

Joseph Scott Warmus

Simone Sciabola

Michael L Vazquez

Mihir D Parikh

Jinshan Michael Chen

Luis Angel Martinez-Alsina

Colin Richard Rose

James M Duerr

The present invention provides novel imidazo[4,5-c]quinoline derivatives of Formula (I), and the pharmaceutically acceptable salts thereof I wherein R, Rand Rare as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of Formula I and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy. 

Imidazo[4,5-C]quinoline derivatives as LRRK2 inhibitors

Described herein are pyrrolo{2,3-d}pyrimidine derivatives, their use as Janus Kinase (JAK) inhibitors, pharmaceutical compositions containing them, and therapeutic uses thereof.

Pyrrolo[2,3-d]pyrimidine derivatives

The present invention provides novel imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives of Formula (I), and the pharmaceutically acceptable salts thereof wherein R, R, R, R, R, R, R, X and Z are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of Formula (I) and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.

Imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives as LRRK2 inhibitors

The present invention relates to compounds of the Formula I wherein R, R, R, R, R, Rand A are as defined. Compounds of the Formula I have activity inhibiting production of A&#x3b2;-peptide. The invention also relates to pharmaceutical compositions and methods for treating diseases and disorders, for example, neurodegenerative and/or neurological disorders, e.g., Alzheimer's disease, in a mammal comprising compounds of the Formula I.

Imidazole compounds for the treatment of neurodegenerative disorders

The present invention relates to compounds of Formula I wherein R, R, R, R, R, Rand A are as defined. Compounds of Formula I have activity inhibiting production of A&#x3b2;-peptide. The invention also relates to pharmaceutical compositions and methods for treating diseases and disorders, for example, neurodegenerative and/or neurological disorders, e.g., Alzheimer's disease, in a mammal comprising compounds of Formula I.

Imidazole compounds for the treatment of neurological disorders

The present invention relates to compounds of the Formula I wherein R, R, R, m, and n are as defined. Compounds of the Formula I have activity inhibiting production of A&#x3b2;-peptide. The invention also relates to pharmaceutical compositions and methods for treating disorders and diseases, for example, neurodegenerative and/or neurological disorders, e.g., Alzheimer's disease, in a mammal comprising compounds of the Formula I.

Sulfonamide compounds for the treatment of neurodegenerative disorders

Growing community of inventors

Pawcatuck, CT, United States of America

Karen Jean Coffman